Literature DB >> 26092579

'The waiting game': are current chlamydia and gonorrhoea near-patient/point-of-care tests acceptable to service users and will they impact on treatment?

Lindsay M Atkinson1, Dayan Vijeratnam2, Reena Mani2, Raj Patel3.   

Abstract

The objective of this study was to assess the length of time service users were prepared to wait for chlamydia and gonorrhoea (CT/GC) near-patient/point-of-care test (NP-POCT) results and to determine the possible effect on management. Individuals attending two UK clinics from November 2013 to February 2014 were surveyed asking the maximum length of time they would wait for CT/GC NP-POCT results after consultation. Linked CT/GC prevalence and treatment rates were analysed. A total of 1817 participants were surveyed, and 1356 provided CT/GC NAAT samples, in which it was found that 115 (8.5%) could wait over 90 minutes in clinic for their result. 115 received treatment at consultation, of which 50 were CT/GC negative and 12 were treated for urethritis or cervicitis; 38 attended as CT/GC contacts. Six of this population would have waited over 90 minutes were NP-POCTs available. A total of 129 tested CT/GC positive, of whom 65 were treated at their consultation, 61 at a later date, and three were untreated. Twelve of these 129 patients would also have waited over 90 minutes for a NP-POCT result. We conclude that 90-minute NP-POCTs are not acceptable to most clinic attendees and would not have impacted on treatment rates or inappropriate prescribing, and 20-minute NP-POCTs show a marginal benefit in treating CT/GC. While NP-POCTs for CT/GC are promising, they must meet client expectations and enhance disease management in order to be accepted by patients and clinicians.
© The Author(s) 2015.

Entities:  

Keywords:  Sexually trasnmitted infection; chlamydia; diagnosis; gonorrhoea; point-of-care test; testing; time to result; waiting time

Mesh:

Year:  2015        PMID: 26092579     DOI: 10.1177/0956462415591414

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  10 in total

1.  Performance of the Atlas Genetics Rapid Test for Chlamydia trachomatis and Women's Attitudes Toward Point-Of-Care Testing.

Authors:  Lea E Widdice; Yu-Hsiang Hsieh; Barbara Silver; Mathilda Barnes; Perry Barnes; Charlotte A Gaydos
Journal:  Sex Transm Dis       Date:  2018-11       Impact factor: 2.830

2.  Development and Evaluation of a Point-of-Care Test in a Low-Resource Setting with High Rates of Chlamydia trachomatis Urogenital Infections in Fiji.

Authors:  Deborah Dean; Sumeetha Swaminathan; Mike Kama; Sophie Goemans; Daniel Faktaufon; Noor Alnabelseya; Dawn Spelke; Kamin Kahrizi; Matthew Black; Debkishore Mitra
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

3.  Comparing different technologies for active TB case-finding among the homeless: a transmission-dynamic modelling study.

Authors:  Tendai Mugwagwa; Helen R Stagg; Ibrahim Abubakar; Peter J White
Journal:  Sci Rep       Date:  2018-01-23       Impact factor: 4.379

4.  Impact of deploying multiple point-of-care tests with a 'sample first' approach on a sexual health clinical care pathway. A service evaluation.

Authors:  Emma M Harding-Esch; Achyuta V Nori; Aseel Hegazi; Marcus J Pond; Olanike Okolo; Anthony Nardone; Catherine M Lowndes; Phillip Hay; S Tariq Sadiq
Journal:  Sex Transm Infect       Date:  2017-02-03       Impact factor: 3.519

5.  Beyond syndromic management: Opportunities for diagnosis-based treatment of sexually transmitted infections in low- and middle-income countries.

Authors:  Nigel J Garrett; Farzana Osman; Bhavna Maharaj; Nivashnee Naicker; Andrew Gibbs; Emily Norman; Natasha Samsunder; Hope Ngobese; Nireshni Mitchev; Ravesh Singh; Salim S Abdool Karim; Ayesha B M Kharsany; Koleka Mlisana; Anne Rompalo; Adrian Mindel
Journal:  PLoS One       Date:  2018-04-24       Impact factor: 3.240

6.  Mobile nucleic acid amplification testing (mobiNAAT) for Chlamydia trachomatis screening in hospital emergency department settings.

Authors:  D J Shin; P Athamanolap; L Chen; J Hardick; M Lewis; Y H Hsieh; R E Rothman; C A Gaydos; T H Wang
Journal:  Sci Rep       Date:  2017-07-03       Impact factor: 4.996

7.  A 30-Min Nucleic Acid Amplification Point-of-Care Test for Genital Chlamydia trachomatis Infection in Women: A Prospective, Multi-center Study of Diagnostic Accuracy.

Authors:  E M Harding-Esch; E C Cousins; S-L C Chow; L T Phillips; C L Hall; N Cooper; S S Fuller; A V Nori; R Patel; S Thomas-William; G Whitlock; S J E Edwards; M Green; J Clarkson; B Arlett; J K Dunbar; C M Lowndes; S T Sadiq
Journal:  EBioMedicine       Date:  2018-01-10       Impact factor: 8.143

8.  Diagnostic accuracy of a prototype rapid chlamydia and gonorrhoea recombinase polymerase amplification assay: a multicentre cross-sectional preclinical evaluation.

Authors:  E M Harding-Esch; S S Fuller; S-L C Chow; A V Nori; M A Harrison; M Parker; O Piepenburg; M S Forrest; D G Brooks; R Patel; P E Hay; N Fearnley; M J Pond; J K Dunbar; P D Butcher; T Planche; C M Lowndes; S T Sadiq
Journal:  Clin Microbiol Infect       Date:  2018-06-12       Impact factor: 8.067

9.  Right-Sizing Technology in the Era of Consumer-Driven Health Care.

Authors:  Eszter Deak; Elizabeth M Marlowe
Journal:  Clin Microbiol Newsl       Date:  2017-07-19

10.  Antimicrobial resistance point-of-care testing for gonorrhoea treatment regimens: cost-effectiveness and impact on ceftriaxone use of five hypothetical strategies compared with standard care in England sexual health clinics.

Authors:  Emma M Harding-Esch; Susie E Huntington; Michael J Harvey; Georgie Weston; Claire E Broad; Elisabeth J Adams; S Tariq Sadiq
Journal:  Euro Surveill       Date:  2020-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.